The Timing and Probability of Switching to Second-line Regimen - An application to Second-Line Antiretroviral Therapy in India.

Felipa, de Mello-Sampayo (2014): The Timing and Probability of Switching to Second-line Regimen - An application to Second-Line Antiretroviral Therapy in India.

Abstract

Health fluctuations render the outcome of any treatment switch uncertain, so that decision makers might have to wait for more information before optimally switching treatments. This paper sets up a stochastic model that provides an optimal rule for the timing of treatment switch. The results of the model were then tested empirically with patient-based data on first-line and second-line antiretroviral treatment in India. The empirical results support the findings of the analytical model.

• Item Type: MPRA Paper
• Language: English
• Keywords: Uncertainty; Utility Function; Health; Antiretroviral Treatment; Treatment Switch
• Subjects: C - Mathematical and Quantitative Methods > C6 - Mathematical Methods ; Programming Models ; Mathematical and Simulation Modeling > C61 - Optimization Techniques ; Programming Models ; Dynamic Analysis; D - Microeconomics > D8 - Information, Knowledge, and Uncertainty > D81 - Criteria for Decision-Making under Risk and Uncertainty; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

Aitchison, J. and Brown, J. (1957), The Lognormal Distribution, Cambridge: Cambridge University Press.

Ajose, O., Mookerjee, S., Mills, E. J., Boulle, A. and Ford, N. (2012), “Treatment out- comes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis”, AIDS 261, 929-38.

Claxton, K. (1999), “The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies”, Journal of Health Economics 18, 342-64.

Claxton, K., Eggington, S., Ginnelly, L., Griffin, S., McCabe, C., Philips, Z., Tappenden, P. and Wailoo, A. (2005), A pilot study of value of information analysis to support research recommendations for NICE., Technical report, Centre for Health Economics, CHE Research Paper 4, University of York.

Cohen, O. (2000), “Antiretroviral therapy: time to think strategically”, The Lancet 132, 320-22.

de Mello-Sampayo, F. (2014), “The timing and probability of treatment switch under cost uncertainty: an application to patients with GIST”, Value in Health 17, 215-22.

Dixit, A. (1989a), “Entry and exit decisions under uncertainty”, Journal of Political Economy 97, 620-638.

Dixit, A. (1989b), “Hysteresis, import penetration, and exchange rate pass-through”, Quarterly Journal of Economics 104, 205-228.

Dixit, A. (1993), “The art of smooth pasting”, Fundamentals of Pure and Applied Economics 55.

Dixit, A. and Pindyck, R. (1994), Investment under Uncertainty, Princeton: Princeton University Press.

Freedberg, K. A., Kumarasamy, N., Losina, E., Cecelia, A. J., Scott, C. A., Divi, N. and et al. (2007), “Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy”, AIDS 21, 117-28.

Gupta, S. B., Pujari, S. N., Joshi, S. R. and Patel, A. K. (2007), “API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). endorsed by the AIDS Society of India”, Journal of Association of Physicians of India 54, 57-74.

Harrington, M. and Carpenter, C. (2000), “Hit HIV-1 hard, but only when necessary”, The Lancet 355, 2147-152.

Lasserre, P., Moatti, J. P. and Soubeyran, A. (2006), “Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning”, Journal of Health Economics 25, 1603-11.

Levy, M. and Nir, A. R. (2012), “The utility of health and wealth”, Journal of Health Economics 31, 379-392.

Meyer, E. and Rees, R. (2012), “Watchfully waiting: Medical intervention as an optimal investment decision”, Journal of Health Economics 31, 349-58.

Mills, E. J., Bakanda, C., Birungi, J., Chan, K., Ford, N., Cooper, C. L. and et al. (2006), “Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi”, The Lancet 37, 579-598.

Mills, E. J., Bakanda, C., Birungi, J., Chan, K., Ford, N., Cooper, C. L. and et al. (2011), “Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.”, Annals of Internal Medicine 155, 209-216.

Oksendal, B. (2003), Stochastic Differential Equations: An Introduction with Applications, Berlin/Heidelberg/New York: Springer.

Pindyck, R. (1988), “Irreversible investment, capacity choice, and the value of the firm”, American Economic Review 78, 969-985.

Sculpher, M. and Claxton, K. (2005), “Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence?”, Value in Health 8, 433-46.

UNAIDS/WHO (2010), Country progress report, India, Technical report, UNAIDS/WHO, Available from http://www.unaids.org (accessed May 2013).

Zivin, J. G. and Neideill, M. (2009), “Medical technology adoption, uncertainty, and irreversibilities: Is a bird in the hand really worth more than two in the bush?”, Health Economics 19, 142-53.